The approach (s), which is/are currently followed to produce human monoclonal antibodies, is/are known as
A -
transformation of antigen specific B lymphocytes (EBV)
B -
hybridization of 6-thioguanine-resistant human plasmacytoma with immune human lymphocytes
C -
combination of EB Vand hybridoma techniques
D -
All of these
3-
Some cross reactions with monoclonal antibodies (MAbs) can occur. Unexpected cross reactions occur more frequently with
A -
Ig MAbs
B -
IgG
C -
IgA
D -
IgE
4-
Preliminary clinical results with a humanized antibody against the interleukin-2 receptor have suggested the
A -
absence of human immune response against murine proteins (HAMA) response
B -
presence of HAMA response
C -
poor recognition of immunoglobulin, Ig constant regions
D -
All of the above
5-
The cross linkage of antigens by antibodies is known as
A -
agglutination
B -
complement fixation
C -
a cross reaction
D -
All of these
6-
In monoclonal antibody technology, tumor cells that can replicate endlessly are fused with mammalian cells that produce an antibody. The result of this cell fusion is a
